The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
about
The role of lipoxin A4 in endometrial biology and endometriosisThe pharmacological management of osteoporosisSteroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targetingRegulation of Estrogen Receptor α Expression in the Hypothalamus by Sex Steroids: Implication in the Regulation of Energy HomeostasisGenome-wide signatures of transcription factor activity: connecting transcription factors, disease, and small moleculesDesign of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissuesA model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen.Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data.In search of novel drug target sites on estrogen receptors using RNA aptamers.Research resource: modulators of glucocorticoid receptor activity identified by a new high-throughput screening assay.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer.Obesity, cholesterol metabolism, and breast cancer pathogenesisThe role of hypothalamic estrogen receptors in metabolic regulation.What have we learned about GPER function in physiology and disease from knockout mice?The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.Structural and functional profiling of environmental ligands for estrogen receptors.Dynamic transcription factor networks in epithelial-mesenchymal transition in breast cancer models.Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.A systematic in silico mining of the mechanistic implications and therapeutic potentials of estrogen receptor (ER)-α in breast cancer.Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanismsTamoxifen and Src kinase inhibitors as neuroprotective/neuroregenerative drugs after spinal cord injuryBreast cancer medications and vision: effects of treatments for early-stage disease.Ubiquitylation of nuclear receptors: new linkages and therapeutic implications.Modulation of Estrogen Response Element-Driven Gene Expressions and Cellular Proliferation with Polar Directions by Designer Transcription RegulatorsInternational Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic ModulatorsAnalysis of chromatin dynamics during glucocorticoid receptor activationDrug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii GrowthDissecting rapid estrogen signaling with conjugates.Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patientsBicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides.Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.Thiophene-core estrogen receptor ligands having superagonist activity.Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolismMinireview: dynamic structures of nuclear hormone receptors: new promises and challenges.Triaryl-substituted Schiff bases are high-affinity subtype-selective ligands for the estrogen receptor.Immunomodulatory effects of anti-estrogenic drugs.Evolution of the tissue selective estrogen complex (TSEC).A Residue-Resolved Bayesian Approach to Quantitative Interpretation of Hydrogen-Deuterium Exchange from Mass Spectrometry: Application to Characterizing Protein-Ligand Interactions.Oestrogens as apoptosis regulators in mammalian testis: angels or devils?
P2860
Q24564121-7A5A85B8-95DF-482F-AC3C-86C7EEC1E579Q24605290-DBC5495E-FD8A-4681-B351-00E2C0D69B10Q26745907-1E74871B-4A04-40B4-A09C-496872D8781DQ26778407-739CD429-B646-40A4-AA51-05574E44313BQ28536750-323CE042-1105-4A51-BACE-D41B581AB535Q28828683-436FC7A8-F2D2-462F-817E-9237F24FE885Q30535835-0924E834-469D-478C-A212-A1A88935CE93Q30659580-7637EEB7-1C73-4040-9C8E-F8952E35890FQ33632085-8E9741E8-8999-4277-8F4F-F82ED962377FQ33821604-2CD47860-2296-44EB-899B-A2B55364953FQ34022694-90FC82EF-25BD-4B34-8859-BC4D75D346DAQ34171827-48AA1E88-1862-4F00-89BF-8C23192BE140Q34204836-5C094E5C-4D3A-4AD4-B458-0729DA14AE92Q34243150-50D76825-DFF7-410F-9F7E-7F5878A8F0A4Q34485765-1A80F1CD-1B4A-4DED-8D44-BCB81B9D9230Q34534031-F2C387D9-410D-4A3B-91F4-DA07C2E64A77Q34632938-357BA5DB-4880-4066-8841-01ED21A681DCQ34672166-6D43DE79-5EBA-48F0-9247-AF881376BD28Q34747157-93B80BB8-71D5-4BBA-AC75-7EFC8300C2A7Q35116627-A35F85E7-1C99-48CD-BFDF-42189479A0CDQ35164591-7AA0AA64-BF79-4959-952D-4E9DFC9DD659Q35403338-F0707E85-B2EA-400E-88F3-891AC5564641Q35496778-8BB0FA39-6031-46BA-9DBA-F6D5F1E3209CQ35688891-2EDFCF9D-346C-4767-9FE3-3B449CF23F12Q35752145-A7E46762-B139-41F0-9E13-548233311B93Q35795751-6CD48245-3AF3-45E0-9459-734B788CA7E5Q35943946-1389E0D2-DDF9-41BB-B99C-CA4F948C3781Q36052648-6F4F5221-32E6-4F06-9913-307AB0E6C12CQ36055356-49967F51-8D9A-4F62-BF06-1164D80471B8Q36310554-EBD8D5E0-9820-4607-9A2E-B0CBF405DB2FQ36405734-EBD4D86B-A207-4E44-B64F-7769390BAE69Q36450456-5C04255D-F0B9-4D82-B51A-1ACA15F6AE5CQ36883747-4226FE26-790A-454F-A666-B22C4D918BEEQ37132250-A993A9E6-5EE0-4AFB-8E87-1CEB60F0F94CQ37496703-FD295086-7213-46E8-A1D4-681B6960952FQ37727682-38CBFA8A-5DC2-4E93-B08F-1C6AAB7DF902Q38023107-B824DD17-9029-4FF0-A110-DEC200919C76Q38077503-7B9BEADC-FFEC-488F-B599-18271F18CB38Q38435111-8ED6EBF5-8BCC-4791-AC67-E5DDB2796543Q38563707-CE746A40-1CD2-4B1C-9569-FCEAF0251C57
P2860
The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The molecular mechanisms under ...... ug discovery in breast cancer.
@ast
The molecular mechanisms under ...... ug discovery in breast cancer.
@en
The molecular mechanisms under ...... ug discovery in breast cancer.
@nl
type
label
The molecular mechanisms under ...... ug discovery in breast cancer.
@ast
The molecular mechanisms under ...... ug discovery in breast cancer.
@en
The molecular mechanisms under ...... ug discovery in breast cancer.
@nl
prefLabel
The molecular mechanisms under ...... ug discovery in breast cancer.
@ast
The molecular mechanisms under ...... ug discovery in breast cancer.
@en
The molecular mechanisms under ...... ug discovery in breast cancer.
@nl
P2860
P1476
The molecular mechanisms under ...... ug discovery in breast cancer.
@en
P2093
Donald P McDonnell
Suzanne E Wardell
P2860
P304
P356
10.1016/J.COPH.2010.09.007
P577
2010-12-01T00:00:00Z